Objective: Perioperative 5-fluorouracil, oxaliplatin, and docetaxel (FLOT) chemotherapy is the gold standard treatment for locally advanced gastric cancer (LAGC). The present study aimed to evaluate the efficacy and safety of perioperative FLOT and the prognostic role of the associated clinicopathological factors. Material and Methods: A retrospective analysis was conducted with 48 patients having gastric adenocarcinoma (stage cT2-4 and/or N+ M0) who received perioperative FLOT (four preoperative and four postoperative 2-week cycles) and underwent surgery for LAGC. The clinical and demographic characteristics of the patients, pretreatment laboratory values, and histological features were recorded. Univariate and multivariate Cox regression analyses were conducted. Results: The median age of the patients was 59.5 years (age range, 28-73 years). R0 resection was possible in 86% of the patients who underwent surgery. The objective response rate was 58.3%, the median disease-free survival was 25.4 months (95% CI, 13.2-37.6), and the median overall survival (OS) was 42.9 months (95% CI,-/-). The 2-year OS was 69.1%. It was revealed that ≥ pN2 disease, a positive surgical margin (SM), the presence of perineural invasion (PNI), a poor pathological response to neoadjuvant therapy, and the use of an adjuvant chemotherapy regimen other than FLOT exerted a negative effect on survival. In the multivariate analysis, PNI and SM were revealed as independent factors. Conclusion: The study presents real-life data that demonstrate the effectiveness and feasibility of perioperative FLOT. The presence of PNI and positive SM were revealed to be the negative prognostic parameters for survival.